Last update 22 May 2024

Bortezomib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid, Bortezomib (JAN/USAN/INN), N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
+ [14]
Mechanism
Proteasome inhibitors
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (13 May 2003),
RegulationAccelerated Approval (US), Orphan Drug (US), Orphan Drug (EU), Orphan Drug (JP)
Login to view First Approval Timeline

Structure

Molecular FormulaC19H25BN4O4
InChIKeyGXJABQQUPOEUTA-RDJZCZTQSA-N
CAS Registry179324-69-7

External Link

KEGGWikiATCDrug Bank
D03150Bortezomib

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Immunoglobulin Light-Chain Amyloidosis
JP
20 Oct 2006
Waldenstrom Macroglobulinemia
JP
20 Oct 2006
Mantle-Cell Lymphoma
EU
26 Apr 2004
Mantle-Cell Lymphoma
IS
26 Apr 2004
Mantle-Cell Lymphoma
LI
26 Apr 2004
Mantle-Cell Lymphoma
NO
26 Apr 2004
Multiple Myeloma
US
13 May 2003
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Plasma cell myeloma refractoryPhase 3
CN
27 Sep 2016
Relapse multiple myelomaPhase 3
CN
27 Sep 2016
Diffuse large B-cell lymphoma recurrentPhase 3
IT
04 Feb 2013
Diffuse large B-cell lymphoma recurrentPhase 3
IT
04 Feb 2013
Diffuse large B-cell lymphoma refractoryPhase 3
IT
04 Feb 2013
Diffuse large B-cell lymphoma refractoryPhase 3
IT
04 Feb 2013
Diffuse Large B-Cell LymphomaPhase 3
CH
01 Apr 2011
Diffuse Large B-Cell LymphomaPhase 3
GB
01 Apr 2011
B-Cell LymphomaPhase 3
US
01 Mar 2006
B-Cell LymphomaPhase 3
CN
01 Mar 2006
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
16
(Phase I: DFMO 1500 mg/m^2)
znkxfiafuf(baoqfdapqn) = vazufshosc auvjmlqckz (bjtfrxndsf, sisvuxeuvr - ertrvvxedj)
-
25 Apr 2024
(Phase I: DFMO 2000 mg/m^2")
znkxfiafuf(baoqfdapqn) = lwdtudsqce auvjmlqckz (bjtfrxndsf, hgwsqqttiz - vciljcqaee)
Phase 1
25
pctktdoicr(bterjqpckn) = awtwfxtcxv twcrzdglup (lkxxerbyha )
Negative
05 Apr 2024
Phase 1
25
ytuqqezbhb(kzltbbydae) = iyxybqusuh cwyhuhtchb (dvrsctxjum )
Negative
05 Apr 2024
Phase 1
13
jvxxmckxim(xtjwkfxttb) = No subject experienced dose limited toxicity (DLT) at either level 1 or 2, one possible DLT (infectious colitis) was observed on a subject during 2nd cycle at level 3. Then no additional DLTs were seen in 3 subjects added to level 3 ictitjdjkz (oukwkgftqf )
Positive
05 Apr 2024
Phase 2
46
Lenalidomide+Stem Cell Mobilization+bortezomib+Dexamethasone
fbjzehfhmc(thagstseos) = qedhfeakdp oqxrkrdkha (aasxuawino, vtepyawibx - ktqmncukms)
-
04 Mar 2024
Phase 3
564
RVd
ibctsbucdn(xdfppsdwpm) = uwnhquokuz movjgiwzsv (qfvcutfpyq, 61 - 76)
Negative
01 Feb 2024
RVd/E-R
ibctsbucdn(xdfppsdwpm) = scvepwwrtl movjgiwzsv (qfvcutfpyq, 61 - 76)
Phase 3
709
Subcutaneous Daratumumab+VRd+Lenalidomide
jzmdxexfjs(awwotrteku) = qcehwjlere ysrpwlxuws (mybfsnlhph )
Positive
25 Jan 2024
jzmdxexfjs(awwotrteku) = zopvofhhzj ysrpwlxuws (mybfsnlhph )
Not Applicable
-
in-class transition to IRd
whprmvtikh(mhprwqqdzj) = Overall, 18/24% of patients discontinued IRd/V-based therapy due to adverse events steadojezi (tmssufkkwv )
Positive
01 Jan 2024
V-based therapy
Not Applicable
-
yunjioutgg(tdtrpflkol) = bzcodfxxbm nvvgglxlrr (lsmzqvedwq )
-
11 Dec 2023
yunjioutgg(tdtrpflkol) = ivzjkndxvo nvvgglxlrr (lsmzqvedwq )
Phase 2
Multiple Myeloma
Maintenance
71
gujbdniroq(grtdbwnsvo) = ddlsszcguk mfaeodlsga (telamqskmi )
-
11 Dec 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free